An observational study in Diabetes, Diabetes Mellitus and Type 1 Diabetes, sponsored by Insulet Corporation. Active, not recruiting at 24 sites in France. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Insulet Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is the only one that started in 2025, is one of 3 observational ones, and was the 11th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:
Insulet Corporation · Sites in New Zealand
Ages 2–70 · Healthy volunteers
Insulet Corporation · Sites in United States
Ages 14–75
Insulet Corporation · Sites in France
Ages 2+
Insulet Corporation · Sites in United States
Ages 2+
By country, each count listing its studies:
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 304 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 80 across the 11 interventional studies, 304 across the 3 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
5 of the studies in Diabetes Mellitus, Type 1 by Insulet Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593625Insulet CorporationEvaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D | 2026-12-31 |
| NCT07579702Insulet CorporationEfficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System | 2027-02-22 |
| NCT06144554Insulet CorporationPost Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes | 2027-06 |
| NCT07039942Insulet CorporationFrench Prospective Multicentric Study in Real World | 2027-07-30 |
| NCT07317102Insulet CorporationOmnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Twelve-month, real-world, non-interventional, prospective follow-up of adult and pediatric patients aged more than 2 years old, prescribed one of the Dexcom (Dexcom G6 or G7) configurations commercially available of the Omnipod 5 Automated Insulin Delivery System in France.
OPTIMAL-A study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 304 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population contains patients (age ≥ 2 years) with T1DM initiating a commercially available configuration of the Omnipod 5 System using a Dexcom sensor (Dexcom G6 or Dexcom G7) in France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participation of each patient begins at inclusion and continues until the end-of-study visit, 12 months (± 1 month) following first initiation of automated mode of the Omnipod 5 System
Device: Omnipod 5
The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin. The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.
Change in the percentage of time in the 70 - 180 mg/dL range (TIR)
Assess the effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: 12 months following first initiation of automated mode
Percentage of time in the 70 - 180 mg/dL range (TIR)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of time in the 70 - 140 mg/dL range (TIR Tight)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of time below 54 mg/dL (TBR Very Low)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of time below 70 mg/dL (TBR Low)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of time above 180 mg/dL (TAR High)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of time above 250 mg/dL (TAR Very High)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Glucose Management Indicator (GMI)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Glycemic Risk Index (GRI)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Coefficient of variation (CV)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Mean glucose
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Laboratory HbA1c levels (if available)
Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients with ≥ 70% TIR
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients with < 4% TBR Low
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients with < 1% TBR Very Low
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients with GMI ≤ 7%
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients with CV ≤ 36%
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
Percentage of patients achieving combinations of previous CGM-based consensus targets
Assess the achievement of CGM-based consensus targets
Time frame: Up to 12-months following first initiation of automated mode
EuroQoL 5-dimension 5-level questionnaire
Assess patients' general QoL
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Patients aged ≥ 18 years: Diabetes Quality of Life - Brief Clinical Inventory
Assess patients' diabetes-specific QoL
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Patients aged 10-17 years: Diabetes Quality of Life for Youth scale - Short Form (DQOLY-SF)
Assess patients' diabetes-specific QoL
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Insulin Delivery System Rating Questionnaire (IDSRQ) interference sub-score
Assess the interference of the Omnipod 5 System with patients' daily lives
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Patients aged ≥ 18 years: Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs)
Assess patients' satisfaction with the Omnipod 5 System
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Patients aged 13-17 years: Diabetes Treatment Satisfaction Questionnaire, status version - Teens (DTSQs - Teen)
Assess patients' satisfaction with the Omnipod 5 System
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Patients aged 2-12 years: Diabetes Treatment Satisfaction Questionnaire, status version - Parent (DTSQs - Parent)
Assess patients' satisfaction with the Omnipod 5 System
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Pediatric quality of life questionnaire (animated emoji scale - ad hoc)
Assess pediatric patients' quality of life with the Omnipod 5 System
Time frame: At inclusion and 6 and 12 months following first initiation of automated mode
Percentage of time using the System in automated mode
Describe System use
Time frame: 12 months following first initiation of automated mode
Percentage of time using the System in manual mode
Describe System use
Time frame: 12 months following first initiation of automated mode
Percentage of time using "Activity" feature
Describe System use
Time frame: 12 months following first initiation of automated mode
Total daily dose of insulin
Describe System use
Time frame: 12 months following first initiation of automated mode
Number of boluses per day
Describe System use
Time frame: 12 months following first initiation of automated mode
Targets used by patients
Describe System use
Time frame: 12 months following first initiation of automated mode
Bolus/Basal distribution
Describe System use
Time frame: 12 months following first initiation of automated mode
Incidence of severe hypoglycemia
Assess the incidence and type of acute metabolic complications
Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode
Incidence of diabetic ketoacidosis
Assess the incidence and type of acute metabolic complications
Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode
Unscheduled hospitalizations for diabetes or diabetes complications.
Assess the incidence and type of acute metabolic complications
Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode
Percentage of patients still using the Omnipod 5 System at the end of study follow-up.
Assess the rate at which patients stop using the Omnipod 5 system
Time frame: 12 months following first initiation of automated mode
Reasons for having stopped using the Omnipod 5 System
Assess the rate at which patients stop using the Omnipod 5 system
Time frame: 12 months following first initiation of automated mode
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 24 months is close to that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.